BNGO Relative Valuation
BNGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNGO is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for BNGO's competitors is 2.54, providing a benchmark for relative valuation. Bionano Genomics Inc Corp (BNGO) exhibits a P/S ratio of 0.43, which is -83.19% above the industry average. Given its robust revenue growth of -23.86%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Bionano Genomics Inc (BNGO) currently overvalued or undervalued?
What is Bionano Genomics Inc (BNGO) fair value?
How does BNGO's valuation metrics compare to the industry average?
What is the current P/B ratio for Bionano Genomics Inc (BNGO) as of Apr 28 2025?
What is the current FCF Yield for Bionano Genomics Inc (BNGO) as of Apr 28 2025?
What is the current Forward P/E ratio for Bionano Genomics Inc (BNGO) as of Apr 28 2025?